DIAGNOSTIC RADIOLOGY-IMAGING, CHEMOTHERAPY-BRAIN TUMOR

我们动物研究的长期目标是提供 改善临床应用所需的重要信息 动脉化疗治疗脑肿瘤 更 具体而言，我们将继续进行目前的研究， 描述与以下药物相关的药代动力学参数： 动脉内施用化疗剂。 重点 将评估动脉内优势（Rd） 可以通过以下方式来改善药物递送：（1）改变药物递送的方式， 其中BCNU溶解用于输注;（2）使用类固醇和非类固醇 减少脑肿瘤水肿和改善药物疗效类固醇药物 递送，和;（3）使用短半衰期实验 理想地适合于动脉内递送的化疗剂。 还将注意评价以下药物的药代动力学： IA和IV给予FUDR，理论上可以 积极的实际应用，作为一种药物， 与亚硝基脲类药物治疗脑肿瘤有关。 实验结果 将与动脉内给药的理论模型进行比较 交付. 此外，生理和形态参数 例如血流、脑组织水肿和脑肿瘤 将测量超微结构并与 药物递送的药代动力学测量参数。 这项工作 因为很少有定量研究， 脑肿瘤的动脉内化疗已有报道。 人类脑肿瘤的发病率是显着的，结果 传统的治疗方法是很差的。 虽然动脉内 脑肿瘤的化疗为改善 患者预后，关于基本药代动力学的信息 这种方法缺乏。 这些基本信息是必不可少的 以优化药物输送参数。 这些信息 对介入放射学界来说尤为重要 直接参与脑动脉化疗 肿瘤的

The long term objective of our animal research is to provide important information necessary to improve the clinical application of intraarterial chemotherapy for treating brain tumors. More specifically, we will continue our current studies aimed at delineating the pharmacokinetic parameters associated with intraarterial administration of chemotherapeutic agents. Emphasis will be placed on evaluating how the intraarterial advantage (Rd) of drug delivery can be improved through (1) modifying the manner in which BCNU is dissolved for infusion; (2) using steroids and non steroid agents to reduce brain tumor edema and improve drug delivery, and; (3) using a short half-life experimental chemotherapeutic agent ideally suited for intraarterial delivery. Attention will also be given to evaluating the pharmacokinetics of IA and IV administered FUDR, which could theoretically have positive practical application as a drug to be used in combination with nitrosoureas in treating brain tumors. Experimental results will be compared to theoretical models of intraarterial drug delivery. In addition, physiological and morphologic parameters such as blood flow, brain tissue edema, and brain tumor ultrastructure will be measured and correlated with the pharmacokinetic measured parameters of drug delivery. This work is particularly important since very few quantitative studies of intraarterial chemotherapy for brain tumors have been reported. The incidence of human brain tumors is significant and the results of conventional forms of therapy are poor. Although intraarterial chemotherapy for brain tumors has provided some hope of improving patient prognosis, information regarding the basic pharmacokinetics of this approach is lacking. Such basic information is essential in order to optimize drug delivery parameters. This information is particularly important to the Interventional Radiology community which is directly involved in intraarterial chemotherapy of brain tumors.